Schmidt J C, Brieden-Azvedo S, Nietgen G W
Zentrum für Augenheilkunde, Philipps-Universität Marburg.
Klin Monbl Augenheilkd. 2001 Dec;218(12):800-4. doi: 10.1055/s-2001-19691.
Since introduction of brachytherapy using (106)ruthenium plaque therapy for treating malignant choroidal melanomas a number of comparative studies have shown that survival rates are equal between patients who underwent radiation or enucleation. When radiation treatment fails, the patient might be determined to choose removal of the tumor by pars plana vitrectomy.
Between 1995 and 1998 a total number of 48 patients underwent (106)ruthenium plaque irradiation. In 9 patients tumor regression was not sufficient. Two of these nine patients decided explicitly against enucleation and choose to have the tumor removed from within the eye employing pars plana vitrectomy.
Intraoperatively, the previously radiated melanoma was easily removed with the vitrectomy cutter without significant bleeding. Postoperative recovery was without complications. Silicone oil removal was carried out in one patient after one year. Vision 9 months and 2.5 years after surgery was 0.2 and 0.02, respectively. The cosmetic results with parallel axis of the globes were very good and one patient gained binocular vision. No recurrent tumor growth was seen so far. Histologically, no mitotic figures were found.
Malignant choroidal melanomas can be safely removed by pars plana vitrectomy with stable intraocular pressure. Previous radiation therapy alters the tumor, inducing fibrous tissue growth and necrosis of tumor cells. These tissue types are not prone to bleed when they are resected by the vitrectomy cutter. Long time studies have to elucidate the difference in survival rates between patients undergoing enucleation of the eye and patients who chose endoresection of the melanoma by pars plana vitrectomy.
自从采用(106)钌敷贴疗法进行近距离放射治疗恶性脉络膜黑色素瘤以来,多项比较研究表明,接受放疗或眼球摘除术的患者生存率相当。当放射治疗失败时,患者可能会决定选择通过玻璃体切除术切除肿瘤。
1995年至1998年间,共有48例患者接受了(106)钌敷贴照射。9例患者的肿瘤消退不充分。这9例患者中有2例明确决定不接受眼球摘除术,而是选择通过玻璃体切除术从眼内切除肿瘤。
术中,先前接受过放疗的黑色素瘤很容易用玻璃体切割器切除,且出血不明显。术后恢复无并发症。1年后1例患者进行了硅油取出术。术后9个月和2.5年时的视力分别为0.2和0.02。双眼球平行的美容效果非常好,1例患者获得了双眼视力。目前未见肿瘤复发。组织学检查未发现有丝分裂象。
通过玻璃体切除术可安全切除恶性脉络膜黑色素瘤,且眼压稳定。先前的放射治疗会改变肿瘤,诱导纤维组织生长和肿瘤细胞坏死。当这些组织类型用玻璃体切割器切除时不易出血。长期研究必须阐明接受眼球摘除术的患者与选择通过玻璃体切除术进行黑色素瘤眼内切除的患者在生存率上的差异。